ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ALT Altimmune Inc

7.01
0.46 (7.02%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Altimmune Inc NASDAQ:ALT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.46 7.02% 7.01 7.05 7.11 7.39 6.55 6.64 4,119,410 00:59:52

Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference

27/05/2021 12:00pm

GlobeNewswire Inc.


Altimmune (NASDAQ:ALT)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Altimmune Charts.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference, being held June 1 - 4, 2021.

Details on the Jefferies fireside chat presentation are as follows:

 Title: 2021 Jefferies Virtual Healthcare Conference
    
 Presenters: Vipin Garg, Ph.D., Chief Executive Officer
   Scot Roberts, Ph.D., Chief Scientific Officer
   Scott Harris, M.D., Chief Medical Officer
    
 Date/Time: Wednesday, June 2, 2021 at 11:30 am ET

A webcast link to the fireside chat presentation will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor & Media Contacts:  
   
Will Brown Stacey Jurchison
Chief Financial Officer  Sr. Dir, Investor Relations
Phone: 240-654-1450 Phone : 410-474-8200
wbrown@altimmune.com sjurchison@altimmune.com

 

1 Year Altimmune Chart

1 Year Altimmune Chart

1 Month Altimmune Chart

1 Month Altimmune Chart

Your Recent History

Delayed Upgrade Clock